JAZZ
Income statement / Annual
Last year (2023), Jazz Pharmaceuticals plc's total revenue was $3.83 B,
an increase of 4.78% from the previous year.
In 2023, Jazz Pharmaceuticals plc's net income was $414.83 M.
See Jazz Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$3.83 B
|
$3.66 B
|
$3.09 B
|
$2.36 B
|
$2.16 B
|
$1.89 B
|
$1.62 B
|
$1.49 B
|
$1.32 B
|
$1.17 B
|
| Cost of Revenue |
$435.58 M |
$540.52 M |
$440.76 M |
$148.92 M |
$127.93 M |
$121.54 M |
$110.19 M |
$105.39 M |
$102.53 M |
$117.42 M |
| Gross Profit |
$3.40 B |
$3.12 B |
$2.65 B |
$2.21 B |
$2.03 B |
$1.77 B |
$1.51 B |
$1.38 B |
$1.22 B |
$1.06 B |
| Gross Profit Ratio |
0.89 |
0.85 |
0.86 |
0.94 |
0.94 |
0.94 |
0.93 |
0.93 |
0.92 |
0.9 |
| Research and Development
Expenses |
$849.66 M
|
$590.45 M
|
$505.75 M
|
$335.38 M
|
$299.73 M
|
$226.62 M
|
$198.44 M
|
$162.30 M
|
$135.25 M
|
$85.18 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$380.41 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$25.70 M
|
| Selling, General &
Administrative Expenses |
$1.34 B
|
$1.42 B
|
$1.45 B
|
$854.23 M
|
$736.94 M
|
$683.53 M
|
$544.16 M
|
$502.89 M
|
$449.12 M
|
$406.11 M
|
| Other Expenses |
$627.28 M |
$599.17 M |
$525.77 M |
$259.58 M |
$354.81 M |
$201.50 M |
$152.07 M |
$101.99 M |
$98.16 M |
$126.58 M |
| Operating Expenses |
$2.82 B |
$2.61 B |
$2.48 B |
$1.45 B |
$1.39 B |
$1.11 B |
$894.66 M |
$767.18 M |
$682.53 M |
$617.88 M |
| Cost And Expenses |
$3.26 B |
$3.15 B |
$2.92 B |
$1.60 B |
$1.52 B |
$1.23 B |
$1.00 B |
$872.57 M |
$785.06 M |
$735.30 M |
| Interest Income |
$0.00 |
$11.50 M |
$1.80 M |
$99.71 M |
$20.50 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$289.44 M |
$288.24 M |
$278.77 M |
$99.71 M |
$72.26 M |
$77.08 M |
$77.76 M |
$61.94 M |
$56.92 M |
$52.71 M |
| Depreciation &
Amortization |
$638.70 M
|
$629.47 M
|
$552.48 M
|
$278.25 M
|
$370.16 M
|
$216.73 M
|
$165.15 M
|
$113.78 M
|
$98.16 M
|
$126.58 M
|
| EBITDA |
$1.23 B
|
$553.78 M
|
$1.03 B
|
$649.65 M
|
$1.01 B
|
$932.67 M
|
$779.00 M
|
$753.88 M
|
$665.97 M
|
$583.70 M
|
| EBITDA Ratio |
0.32 |
0.3 |
0.22 |
0.43 |
0.46 |
0.45 |
0.47 |
0.48 |
0.48 |
0.48 |
| Operating Income Ratio
|
0.15
|
0.14
|
0.06
|
0.32
|
0.25
|
0.33
|
0.33
|
0.4
|
0.38
|
0.17
|
| Total Other
Income/Expenses Net |
-$280.65 M
|
-$307.26 M
|
-$283.12 M
|
-$102.98 M
|
-$78.07 M
|
-$85.38 M
|
-$87.73 M
|
-$59.21 M
|
-$72.29 M
|
-$44.03 M
|
| Income Before Tax |
$297.93 M |
-$372.78 M |
-$112.84 M |
$275.10 M |
$454.30 M |
$529.46 M |
$441.12 M |
$532.45 M |
$435.93 M |
$151.56 M |
| Income Before Tax Ratio
|
0.08
|
-0.1
|
-0.04
|
0.12
|
0.21
|
0.28
|
0.27
|
0.36
|
0.33
|
0.13
|
| Income Tax Expense |
-$119.91 M |
-$158.65 M |
$216.12 M |
$33.52 M |
-$73.15 M |
$80.16 M |
-$47.74 M |
$135.24 M |
$106.40 M |
$94.23 M |
| Net Income |
$414.83 M |
-$214.14 M |
-$328.95 M |
$238.62 M |
$523.37 M |
$447.10 M |
$487.85 M |
$396.83 M |
$329.54 M |
$58.39 M |
| Net Income Ratio |
0.11 |
-0.06 |
-0.11 |
0.1 |
0.24 |
0.24 |
0.3 |
0.27 |
0.25 |
0.05 |
| EPS |
6.95 |
-3.42 |
-5.51 |
4.28 |
9.22 |
7.45 |
8.13 |
6.56 |
5.38 |
0.98 |
| EPS Diluted |
6.1 |
-3.42 |
-5.51 |
4.22 |
9.09 |
7.3 |
7.96 |
6.41 |
5.23 |
0.93 |
| Weighted Average Shares
Out |
$63.29 M
|
$62.54 M
|
$59.69 M
|
$55.71 M
|
$56.75 M
|
$59.98 M
|
$60.02 M
|
$60.50 M
|
$61.23 M
|
$59.75 M
|
| Weighted Average Shares
Out Diluted |
$72.07 M
|
$62.54 M
|
$59.69 M
|
$56.52 M
|
$57.55 M
|
$61.22 M
|
$61.32 M
|
$61.87 M
|
$63.04 M
|
$62.61 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
